Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Royal Marsden NHS Foundation Trust |
---|---|
Information provided by: | Royal Marsden NHS Foundation Trust |
ClinicalTrials.gov Identifier: | NCT00301288 |
Patients with aggressive Non−Hodgkin−lymphoma treated at first diagnosis with chemotherapy alone or combined chemoradiotherapy can achieve high response rates. However, patients with relapsed lymphoma still have a poor prognosis. Highdose chemotherapy (HDCT) followed by autologous stem cell transplantation (ASCT) is the treatment of choice for these patients. An ASCT allows patients to recieve much higher doses of chemotherapy than usual, to improve the chances of curing the disease. The high−dose of chemotherapy destroys the cells in the patients bone marow and then the patients own cells from either the bone marrow or peripheral blood are used to rescue the patient from intensive treatment. High−dose chemotherapy with autologous stem cell (either bone marrow or peripheral blood) transplantation is used in the treatment of Intermediate/High grade NHL with poor risk disease and in second remission at the Royal Marsden Hospital.
The purpose of the present analysis is to determine independent prognostic factors correlated with the long−term outcome of patients with NHL who received an ASCT between January 1991 and June 2005. Accrual of eligible patients currently under follow−up will be performed in clinic at the time of next appointment. All patients accrued will give informed consent to participate in the study for retrospective case note review, after discussion with a study investigator and after receiving a study information sheet. The results of the analysis will be published in a peer−reviewed medical journal. This will include patients treated at the royal Marsden Hospital only.
Condition | Intervention |
---|---|
Non-Hodgkins Lymphoma |
Procedure: Autologous stem cell transplant |
Study Type: | Observational |
Study Design: | Longitudinal, Defined Population, Retrospective Study |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Inclusion Criteria:
- a) Age over 18 b) Patients with Non-Hodgkin’s Lymphoma who have received an autologous stem cell transplant in the past.
c) Informed written consent
Exclusion Criteria:
Contact: Bhawna Sirohi, MBBS, MD | 0044 208 661 3115 | bhawna.sirohi@rmh.nhs.uk |
Contact: Jacqui Oates | 0044 2086613279 | jacqui.oates@rmh.nhs.uk |
United Kingdom, Surrey | |
Royal Marsden NHS trust | Recruiting |
Sutton, Surrey, United Kingdom, SM2 5PT | |
Contact: Bhawna Sirohi, MBBS, MD 0044 208 661 3115 bhawna.sirohi@rmh.nhs.uk | |
Sub-Investigator: Bhawna Sirohi, MBBs, MD |
Principal Investigator: | David Cunningham, FRCP | Royal Marsden NHS Foundation Trust |
Study ID Numbers: | 2657 |
Study First Received: | March 9, 2006 |
Last Updated: | October 12, 2006 |
ClinicalTrials.gov Identifier: | NCT00301288 |
Health Authority: | United Kingdom: National Health Service |
Lymphatic Diseases Immunoproliferative Disorders Lymphoma, small cleaved-cell, diffuse |
Lymphoproliferative Disorders Lymphoma, Non-Hodgkin Lymphoma |
Neoplasms Neoplasms by Histologic Type Immune System Diseases |